Zhao Wenchen, Li Zhouyue, Hu Yin, Jiang Jinyun, Long Wen, Cui Dongmei, Chen Weiyin, Yang Xiao
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China.
Cont Lens Anterior Eye. 2021 Jun;44(3):101348. doi: 10.1016/j.clae.2020.06.006. Epub 2020 Jun 30.
To analyse the one-month change in subfoveal choroidal thickness (SFChT) of myopic children treated with 0.01 % atropine, orthokeratology (OK), or their combination.
This is a prospective, randomized controlled trial. One hundred fifty-four children aged between 8 and 12 years with a spherical equivalent (SE) of -1.00 to -6.00 diopters were enrolled. Subjects were randomly assigned to receive 0.01 % atropine and orthokeratology (ACO, n = 39), 0.01 % atropine and single vision glasses (atropine, n = 42), orthokeratology and placebo (OK, n = 36), or placebo and single vision glasses (control, n = 37). SFChT was assessed using optical coherence tomography (OCT). Ocular parameters, including axial length (AL), were measured using a Lenstar LS 900.
SFChT significantly increased in the ACO (14.12 ± 12.88 μm, p < 0.001), OK (9.43 ± 9.14 μm, p < 0.001) and atropine (5.49 ± 9.38 μm, p < 0.001) groups, while it significantly decreased in the control group (-4.81 ± 9.93 μm, p = 0.006). The one-month change in SFChT was significantly different between the control and treatment groups (p < 0.001). The results of pairwise comparisons among the treatment groups showed that the magnitude of the SFChT change was larger in the ACO group than in the atropine group (p = 0.002). The changes in the ACO and OK groups were not significantly different (p = 0.326).
The combination of OK and atropine induced a greater increase in SFChT than monotherapy with atropine, which might indicate a better treatment effect for childhood myopia control.
分析使用0.01%阿托品、角膜塑形术(OK)或两者联合治疗的近视儿童黄斑中心凹下脉络膜厚度(SFChT)的1个月变化情况。
这是一项前瞻性随机对照试验。纳入了154名年龄在8至12岁、等效球镜度数(SE)为-1.00至-6.00屈光度的儿童。受试者被随机分配接受0.01%阿托品联合角膜塑形术(ACO组,n = 39)、0.01%阿托品联合单光眼镜(阿托品组,n = 42)、角膜塑形术联合安慰剂(OK组,n = 36)或安慰剂联合单光眼镜(对照组,n = 37)。使用光学相干断层扫描(OCT)评估SFChT。使用Lenstar LS 900测量包括眼轴长度(AL)在内的眼部参数。
ACO组(14.12±12.88μm,p < 0.001)、OK组(9.43±9.14μm,p < 0.001)和阿托品组(5.49±9.38μm,p < 0.001)的SFChT显著增加,而对照组显著降低(-4.81±9.93μm,p = 0.006)。对照组与治疗组之间SFChT的1个月变化存在显著差异(p < 0.001)。治疗组之间的两两比较结果显示,ACO组SFChT变化幅度大于阿托品组(p = 0.002)。ACO组和OK组的变化无显著差异(p = 0.326)。
与单独使用阿托品治疗相比,角膜塑形术与阿托品联合使用可使SFChT有更大程度的增加,这可能表明对儿童近视控制有更好的治疗效果。